Please login to the form below

Not currently logged in
Email:
Password:

Pfizer to close UK manufacturing site

Pfizer says that over 400 jobs will be lost when it closes its remaining manufacturing operations in Sandwich, UK

US-based pharmaceutical company Pfizer has revealed that over 400 jobs will be lost when it closes its remaining manufacturing operations in Sandwich, UK.

Pfizer confirmed the decision to close the Sandwich plant on 11 September in a press statement, but stressed that the closure was part of its previously announced plans to consolidate its worldwide manufacturing operations to manage global capacity and demand more efficiently.

Pfizer, which employs approximately 90,000 people globally, said earlier in 2007 that it needed to shed more than 10,000 jobs to make cost savings after disappointing FY06 results.

Pfizer's vice-president of manufacturing, Tony Maddaluna, said: "It is with regret that we announce our decision to end manufacturing operations in Sandwich after 53 years. This is the latest in a number of global manufacturing changes to ensure we are operating as efficiently and effectively as possible and able to respond to the challenges of today's business environment."

Pfizer added that it would support staff affected by the decision by redeploying them if possible and insisted that the Sandwich site would continue to serve as one of its four key R&D sites across the globe.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...